Development of rational drug combinations with investigational targeted agents.

Development of Rational Drug Combinations with Investigational Targeted Agents

Development of novel combination therapies.

n engl j med 364;11 nejm.org march 17, 2011 985 mics and cell biology have increased the opportunity for rational design of targeted drugs to inhibit the function of specific molecules, including those contributing to the proliferation of cancer cells and pathogenic microorganisms. Although targeted therapies may offer enhanced efficacy and improved selectivity (and therefore less toxicity), mo...

Rational Combinations of Targeted Agents in AML

Despite modest improvements in survival over the last several decades, the treatment of AML continues to present a formidable challenge. Most patients are elderly, and these individuals, as well as those with secondary, therapy-related, or relapsed/refractory AML, are particularly difficult to treat, owing to both aggressive disease biology and the high toxicity of current chemotherapeutic regi...

ALCINDOR and BEAUGER

molecularly targeted anticancer therapy with conventional cytotoxic chemotherapy. Such combinations can come about only through rational design of clinical trials, taking into account the pharmacology and clinical development of the drugs involved. It is therefore worthwhile revisiting classical chemotherapy agents, because this renewed knowledge could provide a foundation for future trials. Ox...

New therapies in the treatment of melanoma.

INTRODUCTION Therapies targeting immune checkpoints (CTLA-4) and the MAP kinase signaling pathway (RAS/RAF/MEK/ERK) have transformed the treatment of advanced melanoma in the past year. Agents aimed at other therapeutic targets of interest are being actively evaluated in the clinic. AREAS COVERED Areas of active therapeutic interest in melanoma include immunotherapy, molecularly targeted ther...